Sugi Predict

Sugi Predict / Compounds / SCHEMBL3765754

SCHEMBL3765754

SCHEMBL3765754

CC(C)(C)OC(=O)N1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.66
▸ NPC1 O15118 2/20 0.66
▸ ALDH1A1 P00352 4/20 0.61
▸ HSD17B10 Q99714 2/20 0.61
▸ USP30 Q70CQ3 1/20 0.61
▸ MAPT P10636 5/20 0.59
▸ LMNA P02545 4/20 0.59
▸ MAPK1 P28482 4/20 0.59
▸ SMN1; SMN2 Q16637 4/20 0.59
▸ NPSR1 Q6W5P4 2/20 0.58
▸ HTT P42858 2/20 0.58
▸ TSHR P16473 1/20 0.58
▸ MEN1 O00255 1/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ CKS1B P61024 1/20 0.56
▸ SKP1 P63208 1/20 0.56
▸ SKP2 Q13309 1/20 0.56
▸ ATM Q13315 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ AR P10275 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13208949 0.91 MAPT (0.58) RAB9ANPC1ALDH1A1HSD17B10USP30
SCHEMBL1473079 0.90 MAPT (0.58) RAB9ANPC1ALDH1A1HSD17B10USP30
SCHEMBL3767565 0.89 MAPT (0.74) RAB9ANPC1ALDH1A1MAPTLMNA
SCHEMBL29157428 0.89 MAPT (0.74) RAB9ANPC1ALDH1A1HSD17B10USP30
SCHEMBL3767461 0.88 MAPT (0.54) RAB9ANPC1ALDH1A1HSD17B10USP30
SCHEMBL17541711 0.88 MAPT (0.67) RAB9ANPC1ALDH1A1HSD17B10MAPT
SCHEMBL3778538 0.87 SMN1; SMN2 (0.59) RAB9ANPC1ALDH1A1HSD17B10USP30
SCHEMBL3764614 0.87 FAAH (0.58) RAB9ANPC1ALDH1A1HSD17B10USP30
SCHEMBL3770715 0.86 MAPT (0.68) ALDH1A1HSD17B10MAPTLMNAMAPK1
SCHEMBL4584400 0.86 MAPT (0.56) RAB9ANPC1ALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398130-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2025-08-26 — — US disclosed
US-12187741-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2025-01-07 — — US disclosed
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2023-04-20 — — US disclosed
CN-109071526-B Acid addition salts of piperazine derivatives 阿森纽荣股份公司 2023-02-28 — — CN disclosed
US-11591327-B2 Acid addition salts of piperazine derivatives ASCENEURON SA (CH) 2023-02-28 — — US disclosed
US-20220411440-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2022-12-29 — — US disclosed
CN-107108601-B Glycosidase inhibitors 阿森纽荣股份公司 2021-08-20 — — CN disclosed
EP-3186243-B1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2021-07-21 — — EP disclosed
US-11046712-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2021-06-29 — — US disclosed
EP-3419976-B1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2021-04-07 — — EP disclosed
US-10336775-B2 Glycosidase inhibitors ASCENEURON SA (CH) 2019-07-02 — — US disclosed
US-20190055233-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2019-02-21 — — US disclosed
US-20170298082-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2017-10-19 — — US disclosed
EP-3186243-A1 GLYCOSIDASE INHIBITORS Asceneuron SA (CH) 2017-07-05 — — EP disclosed
WO-2016030443-A1 GLYCOSIDASE INHIBITORS ASCENEURON SA (CH) 2016-03-03 — — WO disclosed
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 — — US disclosed
WO-2009001127-A1 CYANOCYCLOPROPYLCARBOXAMIDES AS CATHEPSIN INHIBITORS ASTRAZENECA AB (SE) 2008-12-31 — — WO disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 — — US disclosed
CN-101103007-A Amide compound TAKEDA PHARMACEUTICAL (JP) 2008-01-09 — — CN disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055233-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES DNPEP, GAA, SLC30A5 RAB9A 3119/4885NPC1 975/4885ALDH1A1 63/4885
US-20230120169-A1 ACID ADDITION SALTS OF PIPERAZINE DERIVATIVES DNPEP, GAA, SLC30A5 RAB9A 3119/4885NPC1 975/4885ALDH1A1 63/4885
US-20220411440-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 RAB9A 730/4885NPC1 386/4885ALDH1A1 778/4885
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 RAB9A 1416/4885NPC1 1078/4885ALDH1A1 353/4885
US-11591327-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 RAB9A 3119/4885NPC1 975/4885ALDH1A1 63/4885
US-12187741-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 RAB9A 730/4885NPC1 386/4885ALDH1A1 778/4885
US-20170298082-A1 GLYCOSIDASE INHIBITORS GAA, ENGASE, GBA3 RAB9A 730/4885NPC1 386/4885ALDH1A1 778/4885
US-10336775-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 RAB9A 730/4885NPC1 386/4885ALDH1A1 778/4885
US-12398130-B2 Acid addition salts of piperazine derivatives DNPEP, GAA, SLC30A5 RAB9A 3119/4885NPC1 975/4885ALDH1A1 63/4885
US-11046712-B2 Glycosidase inhibitors GAA, ENGASE, GBA3 RAB9A 730/4885NPC1 386/4885ALDH1A1 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.